title: The outcome of hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
abstract: Transcatheter arterial embolization (TAE) has now been widely accepted in the treatment of hepatocellular carcinoma (HCC). Forty-five patients with tissue proven HCC received TAE and were followed up for more than 6 months; 28 of them were followed for more than one year and 13 for 2 years. The embolic materials used were Lipiodol 0.1-0.2 ml/cm2 (tumor area of its maximal diameter), which was prepared by pumping with contrast agent at a ratio of 1:2 and mixed with anticancer drugs (Mitomycin C: 8-10 mg or Adriamycin 40-50 mg), gelform particles 1-2 mm in size were subsequently embolized. The postembolization syndrome: abdominal pain, fever, nausea and vomiting usually subsided within 1-3 weeks. The overall cumulative half-year, 1-year and 2-year survival rates were 77.8%, 57.1% and 46.2%, respectively. Cases with regular follow-up and those with massive type without satellites, esp. when tumor size less than 5 cm, had better survival rates. In contrast, portal vein thrombosis and big tumors (especially with satellites) indicated poor prognosis. In addition, actively treated coexisting peptic ulcer and/or esophageal varices in HCC patients also improved TAE results.
authors.affiliation: Department of Internal Medicine, Kaohsiung Medical College, Taiwan, Republic of China.
authors.forename: M Y
authors.initials: MY
authors.lastname: Hsieh
authors.forename: D K
authors.initials: DK
authors.lastname: Wu
authors.forename: S N
authors.initials: SN
authors.lastname: Lu
authors.forename: L Y
authors.initials: LY
authors.lastname: Wang
authors.forename: W Y
authors.initials: WY
authors.lastname: Chang
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D004317:Doxorubicin / Q000008:administration & dosage*; D004621:Embolization, Therapeutic; D005260:Female; D005500:Follow-Up Studies; D005782:Gels; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D008103:Liver Cirrhosis / Q000150:complications; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D005782:Gels; D008937:Mitomycins; D007459:Iodized Oil; D004317:Doxorubicin